• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Basel Medical Group Ltd

    4/4/25 4:30:11 PM ET
    $BMGL
    Get the next $BMGL alert in real time by email
    6-K 1 form6-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2025

     

    Commission File Number: 001-42527

     

    Basel Medical Group Ltd

     

    6 Napier Road,

    Unit #02-10/11 Gleneagles Medical Centre

    Singapore 258499

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    Appointment of Director

     

    On April 4, 2025, the Board of Directors of Basel Medical Group Ltd, a business company incorporated in the British Virgin Islands (the “Company”), appointed Mr. Keng Leong Fung (Raymond Fung) as a director to the Board. Mr. Raymond Fung was nominated to the Board by Rainforest Capital VCC, which is a majority shareholder of the Company. There are no family relationships between Mr. Raymond Fung and any other directors and officers of the Company.

     

    Mr. Fung is the founder of Basel Medical Group Ltd prior to our listing on Nasdaq and serves as our adviser. He has extensive experience in Family Offices, Merger and Acquisition, Capital Market Advisory, Risk & Compliance and Fund Operations. Prior to founding the Basel Medical Group, he started BaselCorp in 2012 as a corporate and financial services firm which was later merged with Incorp Asia. Being a shareholder of the enlarged group, he was in charge of its family offices and financial services. With a portfolio of 15,000 corporate clients across eight countries, Incorp Asia was eventually sold to Hillhouse Capital in 2023. Before establishing BaselCorp, Mr. Fung was a team manager in Citibank in charge of institutional investment funds compliance and trustee operations. He was also a finance lead in the Singapore Ministry of Defence handling defence budget. He started his career as an auditor in a Singapore audit firm.

     

    Mr. Fung served as a non-executive director for various private companies. He was also the advisor and director to various international non-profit organization set up by the Oil and Gas Safety Council and other medical associations. He was also the honorary chairman for Global Chinese Societies Exchange Association.

     

    Mr. Fung holds a Master of Business Administration from Nanyang Business School, Nanyang Technological University of Singapore, and is a member of the Institute of Singapore Chartered Accountants.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Basel Medical Group Ltd  
         
    By: /s/ Raymond Wai Man Cheung  
    Name: Raymond Wai Man Cheung  
    Title: Chief Executive Officer and Director  
         
    Date: April 4, 2025  

     

     

     

     

    Get the next $BMGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMGL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

      Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The acquisition marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. About Bethesda Medical Pte. Ltd. Bethesda Medical started its first medical establishment in 1995. This year marks their 30 years' anniversary, and at same time, marks the commencement of a new journey with Basel Medical Group. Bethesda Medical has previously won government tende

      4/30/25 12:15:00 AM ET
      $BMGL
    • Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

      Singapore, April 11, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (NASDAQ:BMGL), today announced the signing of a definitive agreement by its subsidiary Basel Medical Group Pte. Ltd. to acquire Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The agreement marks a significant step in Basel Medical Group's strategic expansion in Singapore and the broader Southeast Asian healthcare market. The completion of the acquisition is subject to customary closing conditions and is expected to take place on or around April 30, 2025 or such other date agreed by the parties. Strategic Partnership Evolves into Full Inte

      4/11/25 2:30:00 AM ET
      $BMGL
    • Basel Medical Group Ltd Announces Exercise of Overallotment Option

      Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the "Company") (NASDAQ:BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the full exercise of the overallotment option by the representative of the underwriters of its initial public offering to purchase an additional 330,750 ordinary shares at a price of US$4.00 per share and the closing of such issuance. The shares of the Company commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol "BMGL". The gross proceeds from this ov

      3/19/25 4:10:00 PM ET
      $BMGL

    $BMGL
    SEC Filings

    See more
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      4/30/25 4:15:24 PM ET
      $BMGL
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      4/21/25 4:30:29 PM ET
      $BMGL
    • SEC Form 6-K filed by Basel Medical Group Ltd

      6-K - Basel Medical Group Ltd (0002004489) (Filer)

      4/11/25 6:10:04 AM ET
      $BMGL